uniQure N.V. - Ordinary Shares (QURE): Price and Financial Metrics

uniQure N.V. - Ordinary Shares (QURE): $20.05

-0.55 (-2.67%)

POWR Rating

Component Grades








Add QURE to Watchlist
Sign Up

Industry: Biotech




#161 of 380

in industry

QURE Price/Volume Stats

Current price $20.05 52-week high $28.25
Prev. close $20.60 52-week low $12.98
Day low $19.96 Volume 458,700
Day high $20.80 Avg. volume 544,536
50-day MA $20.14 Dividend yield N/A
200-day MA $20.73 Market Cap 954.06M

QURE Stock Price Chart Interactive Chart >


  • Growth is the dimension where QURE ranks best; there it ranks ahead of 97.8% of US stocks.
  • The strongest trend for QURE is in Growth, which has been heading up over the past 179 days.
  • QURE's current lowest rank is in the Stability metric (where it is better than 7.42% of US stocks).

QURE Stock Summary

  • Of note is the ratio of UNIQURE NV's sales and general administrative expense to its total operating expenses; just 9.6% of US stocks have a lower such ratio.
  • Over the past twelve months, QURE has reported earnings growth of -143.74%, putting it ahead of merely 10.83% of US stocks in our set.
  • Revenue growth over the past 12 months for UNIQURE NV comes in at -79.06%, a number that bests only 2.19% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to UNIQURE NV, a group of peers worth examining would be CARA, AFMD, RGNX, PSTX, and TSVT.
  • QURE's SEC filings can be seen here. And to visit UNIQURE NV's official web site, go to www.uniqure.com.

QURE Valuation Summary

  • In comparison to the median Healthcare stock, QURE's price/sales ratio is 304.55% higher, now standing at 8.9.
  • Over the past 75 months, QURE's price/earnings ratio has gone down 4.

Below are key valuation metrics over time for QURE.

Stock Date P/S P/B P/E EV/EBIT
QURE 2023-05-23 8.9 2.4 -6.2 -6.6
QURE 2023-05-22 9.1 2.4 -6.3 -6.7
QURE 2023-05-19 9.2 2.5 -6.4 -6.8
QURE 2023-05-18 9.0 2.4 -6.3 -6.6
QURE 2023-05-17 8.9 2.4 -6.2 -6.6
QURE 2023-05-16 8.7 2.3 -6.0 -6.4

QURE Growth Metrics

    The 4 year cash and equivalents growth rate now stands at 158.14%.
  • Its 5 year revenue growth rate is now at -75.1%.
  • The 2 year net income to common stockholders growth rate now stands at 360.77%.
QURE's revenue has moved up $36,331,000 over the prior 70 months.

The table below shows QURE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 61.429 -137.47 -125.388
2022-06-30 61.969 -128.636 -114.062
2022-03-31 525.34 303.521 324.467
2021-12-31 524.002 287.959 329.589
2021-09-30 500.397 297.874 320.682
2021-06-30 500.197 303.322 303.438

QURE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • QURE has a Quality Grade of C, ranking ahead of 27.42% of graded US stocks.
  • QURE's asset turnover comes in at 0.884 -- ranking 28th of 682 Pharmaceutical Products stocks.
  • OVID, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with QURE.

The table below shows QURE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.884 0.954 1.955
2021-06-30 1.088 0.954 2.048
2021-03-31 0.105 1.000 -1.161
2020-12-31 0.101 1.000 -1.210
2020-09-30 0.015 1.000 -1.522
2020-06-30 0.012 1.000 -1.234

QURE Price Target

For more insight on analysts targets of QURE, see our QURE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $66.92 Average Broker Recommendation 1.37 (Strong Buy)

uniQure N.V. - Ordinary Shares (QURE) Company Bio

uniQure is a biopharmaceutical company, developing adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company was founded in 1998 and is based in Amsterdam, the Netherlands.

QURE Latest News Stream

Event/Time News Detail
Loading, please wait...

QURE Latest Social Stream

Loading social stream, please wait...

View Full QURE Social Stream

Latest QURE News From Around the Web

Below are the latest news stories about UNIQURE NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.

UPDATE 1-UniQure to sell royalty interest in blood disorder therapy for up to $400 mln

Dutch drug developer uniQure said on Monday it would sell a part of the royalty rights for the world's most expensive treatment Hemgenix to HealthCare Royalty and Sagard Healthcare for up to $400 million in cash. Australian drugmaker CSL Ltd had acquired exclusive global rights to Hemgenix in June 2020 from uniQure, which would retain the rights to future milestones totaling up to $1.5 billion and maintain an interest in the therapy's royalties. CSL late last year gained the U.S. health regulator's approval for Hemgenix - a gene therapy used for treating a rare genetic blood clotting disorder - and set its list price at $3.5 million.

Yahoo | May 15, 2023

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an interest in HEMGENIX® royalties ~ ~ Capped royalty financing provides uniQure non-equity-dilutive capital to advance its broad gene therapy pipeline, including AMT-130 for Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QU

Yahoo | May 15, 2023

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

The latest analyst coverage could presage a bad day for uniQure N.V. ( NASDAQ:QURE ), with the analysts making...

Yahoo | May 14, 2023

UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 9, 2023

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory temporal lobe epilepsy and AMT-162 in SOD1-ALS ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, May 09, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial r

Yahoo | May 9, 2023

Read More 'QURE' Stories Here

QURE Price Returns

1-mo -5.20%
3-mo -5.38%
6-mo -21.83%
1-year 34.11%
3-year -68.07%
5-year -42.80%
YTD -11.56%
2022 9.31%
2021 -42.60%
2020 -49.58%
2019 148.65%
2018 47.12%

Continue Researching QURE

Want to see what other sources are saying about uniQure NV's financials and stock price? Try the links below:

uniQure NV (QURE) Stock Price | Nasdaq
uniQure NV (QURE) Stock Quote, History and News - Yahoo Finance
uniQure NV (QURE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!